Project Name: Collaborative Working relating to improved lipid management in England associated with the implementation of Leqvio® (inclisiran) into the lipid management pathway (the “Programme”)

Start Date and Duration: 29th July 2021 – 31st August 2024

Project Aim:

The principal aim of the Programme is to develop and/or improve patient pathways to support improved lipid management, which is one of the priorities set out in the NHS Long Term Plan, including activities associated with the implementation of Inclisiran in England (the “Aim”).

Expected Outcomes:

  1. Creating a blueprint for future collaborations between industry and NHSE
  2. Evaluating a population health management approach to target large scale health needs across a population
  3. Through the use of implementation research, provide and assess evidence for the implementation of new interventions within a primary care setting in the NHS
  4. Optimized uptake of lipid lowering therapies in line with NICE Guidance
  5. Improved awareness of lipid management pathways in primary care to enable decision points on care which consider holistic range of treatments and interventions available to enable appropriate clinical management of patients
  6. Ensuring equitable and efficient access to NICE approved medication


The Collaborative Project is intended to deliver the following expected benefits to:

  1. patients, patient population of the following patient user groups
    a. Faster access to innovative and cost effective medicines for patients as part of a diagnosis and treatment pathway
    b. Care closer to home
    c. More equitable access to care
    d. Better information on conditions and treatment options
    e. Improved patient outcomes
  2. the NHS
    a. Highlights England as a prime destination to implement innovative medicines faster and more cost-effectively
    b. More patients treated appropriately in primary care
    c. Better use of finite secondary care resources
    d. Supports one of the key priorities set out in the Long Term Plan regarding cardiovascular disease
  3. Novartis
    a. Primary care treatment pathway in place to support population health approach to Inclisiran
    b. Improved reputation across the NHS in England
    c. Better understanding of NHSE&I and the primary care network

UK | July 2021 | 143476